Can-Fite BioPharma (NYSE: CANF) to present Phase 2a pancreatic cancer data
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. reported that positive data from its Phase 2a study of oral Namodenoson in advanced pancreatic ductal adenocarcinoma have been accepted for poster presentation at the ESMO Congress 2026, a leading global oncology meeting. The study in heavily pretreated, predominantly third-line patients achieved its primary safety endpoint and showed encouraging survival with durable disease stabilization, including a patient treated in second line who remains alive for more than 18 months.
Namodenoson, a highly selective A3 adenosine receptor agonist, is also in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial in MASH, while a Phase 2b pancreatic cancer study combining Namodenoson with chemotherapy is being planned.
Positive
- None.
Negative
- None.
Key Figures
Patient survival duration: more than 18 months
Pancreatic cancer study phase: Phase 2a
Planned pancreatic cancer trial phase: Phase 2b
+3 more
6 metrics
Patient survival duration
more than 18 months
One patient receiving Namodenoson as second-line therapy remains alive more than 18 months
Pancreatic cancer study phase
Phase 2a
Namodenoson was evaluated in a Phase 2a study in advanced pancreatic ductal adenocarcinoma
Planned pancreatic cancer trial phase
Phase 2b
Next clinical development step is a planned Phase 2b study combining Namodenoson with chemotherapy
Liver cancer trial phase
Phase 3
Namodenoson is being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma
MASH trial phase
Phase 2b
Namodenoson is enrolling patients in a Phase 2b trial for the treatment of MASH
Clinical study exposure
over 1,600 patients
Company drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies
Key Terms
pancreatic ductal adenocarcinoma (PDAC), A3 adenosine receptor agonist, Metabolic Dysfunction-associated Steatohepatitis (MASH), Orphan Drug Designation, +1 more
5 terms
pancreatic ductal adenocarcinoma (PDAC) medical
"advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation"
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, arising in the cells that line the small ducts which carry digestive juices. It behaves aggressively and is often diagnosed late, like a clogged pipe that causes widespread damage before it’s noticed. For investors, PDAC matters because its poor prognosis and limited approved treatments create a large unmet medical need—meaning successful new therapies can bring significant returns but carry high clinical and regulatory risk.
A3 adenosine receptor agonist medical
"Namodenoson is a highly selective A3 adenosine receptor agonist with a unique mechanism of action"
An a3 adenosine receptor agonist is a drug that binds to and activates a specific protein on cell surfaces called the a3 adenosine receptor, which helps regulate inflammation, pain signals and tissue protection. Think of it as flipping a targeted biological switch to calm harmful processes. Investors watch these drugs because their clinical trial results, safety profile and regulatory approval determine whether they can become new treatments with significant market value and revenue potential.
Metabolic Dysfunction-associated Steatohepatitis (MASH) medical
"a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)"
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.
Orphan Drug Designation regulatory
"Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Can-Fite BioPharma (CANF) announce regarding its pancreatic cancer program?
Can-Fite BioPharma (CANF) announced that positive data from its Namodenoson Phase 2a study in advanced pancreatic cancer were accepted for poster presentation at ESMO Congress 2026, highlighting safety, durable disease stabilization, and encouraging survival in a heavily pretreated patient population.
What are the key findings from CANF's Namodenoson Phase 2a pancreatic cancer study?
The Namodenoson Phase 2a study in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and showed durable disease stabilization with encouraging survival, including predominantly third-line patients and one second-line patient who remains alive for more than 18 months after starting therapy.
How is Can-Fite BioPharma (CANF) planning to advance Namodenoson after the Phase 2a PDAC study?
Following the Phase 2a pancreatic cancer results, Can-Fite BioPharma (CANF) is planning a Phase 2b study of Namodenoson in combination with chemotherapy, based on encouraging clinical findings and preclinical evidence of synergistic anti-tumor activity supporting further development in this difficult-to-treat setting.
What other clinical trials is Namodenoson involved in for Can-Fite BioPharma (CANF)?
Namodenoson for Can-Fite BioPharma (CANF) is being evaluated in a pivotal Phase 3 trial for advanced hepatocellular carcinoma and a Phase 2b trial for MASH, in addition to the completed Phase 2a pancreatic cancer study and its planned Phase 2b combination trial.
What broader pipeline does Can-Fite BioPharma (CANF) report beyond Namodenoson?
Can-Fite BioPharma (CANF) highlights Piclidenoson, which reported topline results and entered a pivotal Phase 3 psoriasis trial, Namodenoson across liver, MASH and pancreatic cancer, and CF602 for erectile dysfunction, with its drugs collectively studied in over 1,600 patients to date.
What regulatory designations has Namodenoson received, according to CANF?
Can-Fite BioPharma (CANF) states that Namodenoson has Orphan Drug Designation in the U.S. and Europe and Fast Track Designation from the U.S. FDA as a second-line treatment for hepatocellular carcinoma, supporting its development in serious liver cancer indications.